ACNS2321: A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas
ACNS2321
What is the goal of the study?
Germinomas account for more than two thirds of intracranial germ cell tumors (GCT).1, 2 The current treatment regimens lead to excellent outcomes, and they typically involve a combination of both chemotherapy and radiotherapy (RT). Reducing the doses and field of RT, and herewith its long-term side effects, while maintaining excellent overall survival (OS) for germinoma patients has been successful.3 Nonetheless, the lowest dose needed to prevent ventricular and local relapses still needs to be determined.
Who can participate in the study?
Please contact the study team listed below to learn more.